<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="pone.0227041.t003" orientation="portrait" position="float">
 <object-id pub-id-type="doi">10.1371/journal.pone.0227041.t003</object-id>
 <label>Table 3</label>
 <caption>
  <title>Eligibility for antiviral therapy for hepatitis B, by international treatment guidelines.</title>
 </caption>
 <alternatives>
  <graphic id="pone.0227041.t003g" xlink:href="pone.0227041.t003" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  <table frame="hsides" rules="groups">
   <colgroup span="1">
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
   </colgroup>
   <thead>
    <tr>
     <th align="left" colspan="2" rowspan="1">EASL 2017</th>
     <th align="left" colspan="2" rowspan="1">WHO 2015</th>
     <th align="left" colspan="2" rowspan="1">Treat-B</th>
    </tr>
    <tr>
     <th align="left" rowspan="1" colspan="1">Criteria</th>
     <th align="left" rowspan="1" colspan="1">n</th>
     <th align="left" rowspan="1" colspan="1">Criteria</th>
     <th align="left" rowspan="1" colspan="1">n</th>
     <th align="left" rowspan="1" colspan="1">Score</th>
     <th align="left" rowspan="1" colspan="1">n</th>
    </tr>
   </thead>
   <tbody>
    <tr>
     <td align="left" rowspan="1" colspan="1">Cirrhosis and detectable HBV DNA</td>
     <td align="left" rowspan="1" colspan="1">8</td>
     <td align="left" rowspan="1" colspan="1">Clinical cirrhosis</td>
     <td align="left" rowspan="1" colspan="1">0</td>
     <td align="left" rowspan="1" colspan="1">2</td>
     <td align="left" rowspan="1" colspan="1">29</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">Significant fibrosis and HBV DNA ≥2,000 IU/ml</td>
     <td align="left" rowspan="1" colspan="1">5</td>
     <td align="left" rowspan="1" colspan="1">APRI &gt;2.0</td>
     <td align="left" rowspan="1" colspan="1">4</td>
     <td align="left" rowspan="1" colspan="1">3</td>
     <td align="left" rowspan="1" colspan="1">10</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">ALT ≥80 U/L and HBV DNA ≥20,000 IU/ml</td>
     <td align="left" rowspan="1" colspan="1">0</td>
     <td align="left" rowspan="3" colspan="1">HBV DNA ≥20,000 IU/ml and ALT elevation and age ≥30 years</td>
     <td align="left" rowspan="3" colspan="1">11</td>
     <td align="left" rowspan="1" colspan="1">4</td>
     <td align="left" rowspan="1" colspan="1">6</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">METAVIR ≥2 and HBV DNA ≥2,000</td>
     <td align="left" rowspan="1" colspan="1">0</td>
     <td align="left" rowspan="2" colspan="1"/>
     <td align="left" rowspan="2" colspan="1"/>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">HBeAg-positive and age ≥30 years</td>
     <td align="left" rowspan="1" colspan="1">12</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">Family history of HCC or cirrhosis</td>
     <td align="left" rowspan="1" colspan="1">0</td>
     <td align="left" rowspan="1" colspan="1"/>
     <td align="left" rowspan="1" colspan="1"/>
     <td align="left" rowspan="1" colspan="1"/>
     <td align="left" rowspan="1" colspan="1"/>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">Subtotal</td>
     <td align="left" rowspan="1" colspan="1">25</td>
     <td align="left" rowspan="1" colspan="1">Subtotal</td>
     <td align="left" rowspan="1" colspan="1">15</td>
     <td align="left" rowspan="1" colspan="1">Subtotal</td>
     <td align="left" rowspan="1" colspan="1">45</td>
    </tr>
   </tbody>
  </table>
 </alternatives>
 <table-wrap-foot>
  <fn id="t003fn001">
   <p>Cirrhosis was defined as liver stiffness &gt;9.5 kPa; Significant fibrosis was defined as liver stiffness &gt;7.9 kPa; ‘Clinical cirrhosis’ was defined as signs of decompensated cirrhosis on physical examination; ALT elevation was defined as 20+ U/L for women and 30+ for men;</p>
  </fn>
  <fn id="t003fn002">
   <p>
    <underline>Abbreviations:</underline> EASL, European Association for the Study of the Liver; WHO, World Health Organization; HBV, hepatitis B virus; ALT, alanine aminotransferase, HBeAg, hepatitis B e antigen, HCC, hepatocellular carcinoma; APRI, AST-to-platelet ratio index
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
